Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

472

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: rasagiline mesylate
DRUG: 1.0 mg rasagiline mesylate
OTHER: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.